Female adults with ethylenmalonic aciduria and methylentretrahydropholate reductase deficiency: two cases report and review the literatura
Article Sidebar
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Downloads
Societal impact
Main Article Content
Abstract
The impact of genomics in clinical medicine has been significant in recent years. Up to 2012, more than 3,000 genetic conditions have been implicated in clinical medicine. Today, with the new methodology of genome sequencing (next-generation sequencing (NGS) and comparative genomic sequencing (CGH), Mendelian conditions have been identified, as well as their role in genetic variations and polygenetic multifactorial disorders that affect the clinical prognosis and response to treatment. The integration of these diagnostic approaches in clinical practice requires an understanding of the basic principles of heredity, genome organization and molecular genetics. Generally, these conditions are single-gene disorders (also known as monogenic disorders), meaning that a single gene mutation is responsible for the disease. The genetic screening test analyzes hundreds of mutations for recessive genetic diseases. This test informs whether or not such mutations are present, which may lead to largescale genotyping in children using multiple molecular probes. We report two cases of young adult women with symptoms and multiple medical consultations with disease recurrence and uncertain diagnosis, who underwent genetic testing and were determined to be carriers of heterozygous and homozygous mutant ethylmalonic aciduria and methylenetetrahydrofolate reductase deficiency, which could be responsible, in part, for their confusing symptoms.
Article Details
References
Colombo M, Cornejo V, Raimann E. Errores innatos en el metabolismo del niño. 2. ed. Santiago de Chile: Editorial Universitaria; 2003.
Weiner DL. Metabolic emergencies. In: Fleisher G, Ludwing S, Henreting F, editors. Textbook of pediatric emergency medicine. 5. ed. Philadelphia: Lippincott- Williams and Wilkins; 2006. p.1193-1206.
Saudubray JM, Chappentier C. Clinical phenotypes: diagnosis/algorithms. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. Metabolic and molecular bases of inherited disease. 8. ed. New York: McGraw-Hill; 2001. p.1327.
Raimann-B E. Diagnóstico de errores innatos del metabolismo. Rev Chil Pediatr. 2008; 79 Supl (1): 92-5.
Kirke PN, Mills JL, Molloy AM, Brody LC, O’Leary VB, Daly L, et al. Impact of the MTHFR C677T polymorphism on risk of neural tube defects: case-control study. BMJ. 2004; 328 (7455):1535-6.
Fenton WA, Rosenberg LE. Inherited disorders of cobalamin transport and metabolism. In:Scriver R, Beaudet AL,Sly WS, Valle D, editors. The metabolic and molecular basis of inherited disease. 7 ed. New York: McGraw Hill;1995.p. 3129–3149.
Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995 May;10(1):111-3.
Kluijtmans LA, Young IS, Boreham CA, Murray L, McMaster D, McNulty H, et al. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. Blood. 2003 apr;101(7):2483-8.
Lewis SJ, Ebrahim S, Davey Smith G. Meta-analysis of MTHFR 677C->T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and Preventive potential of folate? BMJ. 2005 Nov; 331(7524):1053.
Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG, et al. MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002 Oct; 288(16):2023-31.
Kohara K, Fujisawa M, Ando F, Tabara Y, Niino N, Miki T, et al. MTHFR gene polymorphism as a risk factor for silent brain infarcts and white matter lesions in the Japanese general population: The NILS-LSA Study. Stroke. 2003 May;34(5):1130-5.
Tiranti V, D’Adamo P, Briem E, Ferrari G, Mineri R, Lamantea E, et al. Ethylmalonic encephalopathy is caused by mutations in ETHE1, a gene encoding a mitochondrial matrix protein. Am J Hum Genet. 2004 Feb;74(2):239-52.
Pedersen CB, Bross P, Winter VS, Corydon TJ, Bolund L, Bartlett K, et al. Misfolding, degradation, and aggregation of variant proteins. The molecular pathogenesis of short chain acyl-CoA dehydrogenase (SCAD) deficiency. J Biol Chem. 2003 Nov 28;278(48):47449-58.
Gregersen N, Winter VS, Corydon MJ, Corydon TJ, Rinaldo P, Ribes A, et al. Identification of four new mutations in the short-chain acyl-CoA dehydrogenase (SCAD) gene in two patients: one of the variant alleles, 511C-->T, is present at an unexpectedly high frequency in the general population, as was the case for 625G-->A, together conferring susceptibility to ethylmalonic aciduria. Hum Mol Genet. 1998 Apr;7(4):619-27.
Grosso S, Balestri P, Mostardini R, Federico A, De Stefano N. Brain mitochondrial impairment in ethylmalonic encephalopathy. J Neurol. 2004 Jun;251(6):755-6.
Leslie ND. Insights into the pathogenesis of galactosemia. Annu Rev Nutr. 2003;23:59-80.
Brazeal TJ, Farmer JE. Natural Course and Treatment of Neuropsychological Deficits in a Child with Early-treated Galactosemia. Child Neuropsychol. 1999; 5(3):197-209.
Shield JP, Wadsworth EJ, MacDonald A, Stephenson A, Tyfield L, Holton JB, et al.The relationship of genotype to cognitive outcome in galactosaemia. Arch Dis Child. 2000 Sep;83(3):248-50.
Coman DJ, Murray DW, Byrne JC, Rudd PM, Bagaglia PM, Doran PD, et al. Galactosemia, a single gene disorder with epigenetic consequences. Pediatr Res. 2010 Mar;67(3):286-92.
Raghuveer TS, Garg U, Graf WD. Inborn errors of metabolism in infancy and early childhood: an update. Am Fam Physician. 2006 Jun 1; 73(11):1981-90.
Ruiz M, Sánchez-Valverde, Dalmau J, Gomez L. EIM del metabolismo de la galactosa. En : Ruiz M, Sánchez-Valverde, Dalmau J, Gomez L. Tratamiento nutricional de los errores innatos del metabolismo. 2. ed. Madrid: SHS; 2004. p. 56-70.